Suven Life Sciences Ltd

Suven Life Scie. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Suven Life Sciences Ltd

₹ 120 -0.13%
14 Nov - close price
suven.com BSE: 530239 NSE: SUVEN
About

Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]

Key Points

Primary Focus
The company has been working towards developing new molecules/ compounds in the complex CNS (central nervous system) space. [1]
Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer's, delirium, etc. [2]
CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments. [3]

Website BSE NSE
  • Market Cap ₹ 2,613 Cr.
  • Current Price ₹ 120
  • High / Low ₹ 169 / 74.5
  • Stock P/E
  • Book Value ₹ 37.9
  • Dividend Yield 0.00 %
  • ROCE -2.44 %
  • ROE -2.36 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 3.16 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -47.2% over past five years.
  • Company has a low return on equity of -4.56% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Miscellaneous

Part of BSE SmallCap BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
1 4 4 4 4 3 3 4 3 2 2 1 3
11 11 12 11 12 10 9 11 11 12 9 11 16
Operating Profit -10 -7 -7 -7 -7 -7 -6 -7 -8 -9 -7 -10 -14
OPM % -873% -158% -177% -200% -170% -237% -235% -179% -264% -376% -287% -999% -530%
0 0 0 6 0 2 6 6 13 6 4 4 4
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 2 2 2 2 2 2 2 2 1 1
Profit before tax -11 -8 -9 -2 -9 -7 -2 -3 3 -5 -4 -8 -11
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% -24% 0% 0%
-11 -8 -9 -2 -9 -7 -2 -3 3 -5 -3 -8 -11
EPS in Rs -0.58 -0.43 -0.39 -0.11 -0.41 -0.30 -0.10 -0.13 0.13 -0.22 -0.14 -0.35 -0.51
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
258 510 521 499 543 625 286 13 13 12 14 12 8
205 291 361 369 378 392 237 48 44 48 41 43 48
Operating Profit 53 219 159 130 165 233 49 -35 -30 -36 -28 -31 -40
OPM % 21% 43% 31% 26% 30% 37% 17% -279% -226% -308% -204% -264% -473%
1 3 9 19 21 23 27 14 8 5 14 29 18
Interest 14 11 5 6 6 5 2 1 1 1 0 0 0
Depreciation 8 9 12 18 21 21 11 4 4 4 7 6 6
Profit before tax 33 203 152 126 159 230 63 -26 -28 -36 -20 -9 -28
Tax % 6% 29% 28% 20% 23% 31% 38% -47% -19% 0% 0% -11%
31 144 109 100 123 158 39 -14 -23 -36 -20 -8 -27
EPS in Rs 1.76 8.23 5.70 5.24 6.47 8.30 2.05 -0.72 -1.19 -1.66 -0.92 -0.37 -1.22
Dividend Payout % 11% 20% 7% 25% 10% 12% 49% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -31%
5 Years: -47%
3 Years: -5%
TTM: -32%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 4%
TTM: -62%
Stock Price CAGR
10 Years: 25%
5 Years: 44%
3 Years: 9%
1 Year: 41%
Return on Equity
10 Years: 6%
5 Years: -5%
3 Years: -5%
Last Year: -2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 12 12 13 13 13 13 13 13 13 15 22 22 22
Reserves 143 253 547 611 719 854 389 375 352 461 832 824 805
117 91 109 83 71 34 3 6 5 3 2 1 0
56 132 105 68 74 114 35 16 46 7 5 5 10
Total Liabilities 328 487 773 774 876 1,014 439 410 415 486 860 851 837
162 179 172 305 306 308 22 25 21 38 37 28 25
CWIP 4 13 107 7 10 25 0 0 5 4 0 0 0
Investments 0 0 0 23 366 381 359 242 295 426 528 653 705
162 295 494 438 195 301 58 143 95 19 295 170 106
Total Assets 328 487 773 774 876 1,014 439 410 415 486 860 851 837

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
31 121 143 90 147 105 -12 -45 -37 -37 -23 -21
-15 -36 -110 -62 -353 -38 -4 42 2 -107 -349 -1
3 -38 179 -68 -30 -52 5 4 35 146 396 -1
Net Cash Flow 19 47 212 -40 -236 15 -11 1 1 2 24 -22

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 34 47 28 39 31 36 3 66 48 40 22 40
Inventory Days 238 210 165 183 222 329 0
Days Payable 160 109 89 78 91 134
Cash Conversion Cycle 112 148 105 144 162 231 3 66 48 40 22 40
Working Capital Days 50 62 69 77 66 103 56 1,211 1,320 331 470 397
ROCE % 19% 68% 31% 17% 19% 25% 7% -6% -7% -9% -4% -2%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
60.00% 64.98% 64.98% 64.98% 69.56% 69.56% 69.56% 69.56% 69.56% 69.56% 70.26% 70.26%
0.52% 0.45% 0.45% 0.48% 0.46% 0.51% 0.48% 0.50% 0.54% 0.46% 0.45% 0.33%
0.44% 0.46% 0.39% 0.12% 0.11% 0.11% 0.08% 0.01% 0.01% 1.05% 1.05% 1.05%
39.04% 34.11% 34.18% 34.41% 29.85% 29.80% 29.88% 29.92% 29.88% 28.91% 28.21% 28.34%
No. of Shareholders 80,19581,03981,03880,11680,83878,63476,29180,95374,00368,95966,11663,975

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls